Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

6986 results

Sort By:

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Study ID: NCT06238921
Start Date: 2024-12-19
End Date: 2027-02
Study Type

Interventional

Study Phase

Phase2

No. of Participants

31

Intervention / Treatment

Stereotactic Radiation

Zimberelimab

Sacituzumab govitesan

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Source: clinicaltrials.gov

Share:
Add to list

Group Advanced Care Planning Pilot for Veterans

Study ID: NCT06646614
Start Date: 2025-07-15
End Date: 2027-12-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Group Advance Care Planning Education

Sponsor

VA Palo Alto Health Care System

Source: clinicaltrials.gov

Share:
Add to list

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

Study ID: NCT06136884
Start Date: 2023-11-02
End Date: 2028-01-27
Study Type

Interventional

Study Phase

Phase1

No. of Participants

86

Intervention / Treatment

AO-252

Sponsor

A2A Pharmaceuticals Inc.

Source: clinicaltrials.gov

Share:
Add to list

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Study ID: NCT05805371
Start Date: 2024-07-19
End Date: 2028-11-11
Study Type

Interventional

Study Phase

Phase1

No. of Participants

21

Intervention / Treatment

Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes

Biopsy

Biospecimen Collection

Bone Scan

Computed Tomography

External Beam Radiation Therapy

Leukapheresis

Lymphodepletion Therapy

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Study ID: NCT05287399
Start Date: 2022-08-02
End Date: 2024-12-20
Study Type

Interventional

Study Phase

Phase1

No. of Participants

16

Intervention / Treatment

ASC61 200 mg 1

ASC61 200 mg 2

ASC61 300 mg

ASC61 400 mg

ASC61 600 mg

Sponsor

Gannex Pharma Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)

Study ID: NCT05538533
Start Date: 2023-01-06
End Date: 2026-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

12

Intervention / Treatment

46 Gy Radiation Therapy

40 Gy Radiation Therapy

35 Gy Radiation Therapy

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Study ID: NCT05800210
Start Date: 2024-05-03
End Date: 2027-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Miltenyi CliniMACS Prodigy ® system

Sponsor

University of Florida

Source: clinicaltrials.gov

Share:
Add to list

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Study ID: NCT06561360
Start Date: 2024-09-09
End Date: 2027-09-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

86

Intervention / Treatment

Vemurafenib

Obinutuzumab

Cladribine

Rituximab

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Study ID: NCT04560673
Start Date: 2020-07-10
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

380

Intervention / Treatment

Duloxetine

Neurofeedback

Quality-of-Life Assessment

Administration Questionnaire

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Study ID: NCT05579366
Start Date: 2022-12-07
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

764

Intervention / Treatment

Rina-S

Carboplatin

bevacizumab

Pembrolizumab

Sponsor

Genmab

Source: clinicaltrials.gov

Share:
Add to list